Diagnostics

The third edition of DeciBio's Clinical Oncology Biomarker Testing Market Report provides a summary of the current clinical oncology predictive and prognostic testing market landscape, as well as a forward-looking perspective of the market through 2031. Content includes a comprehensive assessment of market size and growth, as well as key drivers, moderators, and trends related to predictive and prognostic biomarker testing in solid tumors.

Blood-based biomarkers are emerging in neurodegenerative disease testing, enabling earlier, less invasive detection and monitoring. This analysis maps activity across clinical trials, pharma pipelines, routine clinical use, and pharma's current utilization to benchmark key biomarkers, disease focus areas, and leading industry players driving this shift.

This report provides a summary of oncology genomics testing practices, oncologist perspectives and experiences with test providers, and expected future utilization behaviors. A subscription to this report includes 4 waves of data, collected on a quarterly basis (4 reports total, delivered once a quarter).

This report provides a summary of oncology genomics testing practices, oncologist perspectives and experiences with test providers, and expected future utilization behaviors in Europe. A subscription to this report includes 2 waves of data, collected biannually.